M Holdings Securities Inc. Makes New $2.45 Million Investment in Johnson & Johnson (NYSE:JNJ)

M Holdings Securities Inc. bought a new position in shares of Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 16,948 shares of the company’s stock, valued at approximately $2,451,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. IFS Advisors LLC lifted its position in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares during the period. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $26,000. Mountain Hill Investment Partners Corp. bought a new position in Johnson & Johnson in the 4th quarter valued at about $29,000. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $32,000. Finally, Conquis Financial LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $33,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $154.08 on Tuesday. The firm’s fifty day simple moving average is $159.38 and its two-hundred day simple moving average is $155.11. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $371.31 billion, a P/E ratio of 23.17, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.29 earnings per share. As a group, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on JNJ. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Wells Fargo & Company lowered their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Leerink Partners reduced their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Barclays upped their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Eight equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $171.50.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.